原发性肝癌患者血清高尔基蛋白73检测临床价值

Clinical value of detecting serum Golgi protein 73 in patients with primary liver carcinoma

目的探讨血清高尔基蛋白73(GP73)检测对原发性肝癌的临床意义。方法采用酶联免疫法检测60例健康者为正常对照组,60例肝良性肿瘤组,132例原发性肝癌治疗前组,82例原发性肝癌有效治疗后组的血清GP73水平,分析比较各组GP73水平,以及将原发性肝癌治疗前组的不同临床参数的GP73水平进行比较分析。结果正常对照组、良性肿瘤组、原发性肝癌治疗前组、原发性肝癌有效治疗后组的血清中GP73水平比较,差异有显著统计学意义(P<0.01)。原发性肝癌治疗前组的GP73水平明显高于正常对照组及肝良性肿瘤组,差异有统计学意义(P<0.01);原发性肝癌有效治疗后组的GP73水平明显低于原发性肝癌治疗前组(P<0.01)。肝癌患者血清GP73水平与合并肝硬化及临床分期有关(P<0.01)。结论 GP73作为一种新的血清肿瘤标志物,对原发性肝癌的早期诊断、疗效监测、临床分期均具有重要的临床意义。

Objective To explore the clinical value of serum golgi protein 73(GP73)detection in patients with primary liver carcinoma(PLC). Methods Technique of enzyme linked immunosorbent assay was used to detect the levels of serum GP73 in the four experimental groups(60 healthy subjects group,82 patients with benign tumor group,132 patients with primary liver carcinoma before treating group,60 patients with primary liver carcinoma after effective treatment group).Then GP73 levels of four experimental groups were compared and analyzed.And different GP73 levels according to different clinical parameters were compared and analyzed in the primary liver carcinoma before treatment group. Results The levels of four groups were statistically difference.The GP73 level of primary liver carcinoma before treatment group was obviously higher than that of normal control group,and hepatic benign tumor control group(P<0.01);the GP73 level of primary liver carcinoma after effective treatment group was obviously lower than that of primary liver cancer before treating group(P<0.01).The serum GP73 levels of liver cancer patient were associated with liver cirrhosis accompanied and clinical staging(P<0.01). Conclusion GP73 are important serological tumor markers.It is useful for the early diagnosis,therapeutic effect monitoring and clinical staging in primary liver carcinoma.